Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 29.
doi: 10.1111/cen.15211. Online ahead of print.

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Annice Mukherjee  1   2 , Susan R Davis  3   4
Affiliations
Review

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Annice Mukherjee et al. Clin Endocrinol (Oxf). .

Abstract

Objective: To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT).

Design: The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data.

Patients: The review focuses on MHT-related outcomes in women with natural-timed menopause captured within observational studies, RCTs, and pooled data from pivotal meta-analyses and reviews.

Measurements: Available published data are scrutinized. Available evidence and notably lacking data from women not adequately represented in published MHT trials, such as those with socioeconomic adversity, significant comorbidities, and minority ethnic backgrounds, are highlighted and deliberated.

Results: The impact of MHT differs significantly between demographics. Current consensus recommendations for MHT emphasize the importance of tailoring type, route, dose, and duration of therapy to individual needs and risk/benefit ratio through shared decision-making. MHT impact can change over time. Current MHT data support its benefits for treating menopause symptoms and a potential window of opportunity in midlife to benefit skeletal health. Limitations of current evidence highlight menopause health inequalities and underscores the need for further research.

Conclusions: This review recommends tailored use of MHT for well-defined indications, recognizing its value for menopause symptom relief and skeletal benefits for many midlife women. MHT may be used as long as benefits outweigh risks, through shared decision-making. There is insufficient clinical evidence to support the long-term use of MHT in some contemporary cohorts of women accessing MHT in clinical practice.

Keywords: hormone replacement therapy; menopause; menopause hormone therapy; menopause transition; perimenopause.

PubMed Disclaimer

References

    1. E. Armeni, S. A. Paschou, D. G. Goulis, and I. Lambrinoudaki, “Hormone Therapy Regimens for Managing the Menopause and Premature Ovarian Insufficiency,” Best Practice & Research Clinical Endocrinology & Metabolism 35, no. 6 (2021): 101561, https://doi.org/10.1016/j.beem.2021.101561.
    1. J. E. Rossouw, G. L. Anderson, R. L. Prentice, et al., “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial,” Journal of the American Medical Association 288, no. 3 (2002): 321–333, https://doi.org/10.1001/jama.288.3.321.
    1. V. Beral, “Breast Cancer and Hormone‐Replacement Therapy in the Million Women Study,” The Lancet 362, no. 9382 (2003): 419–427, https://doi.org/10.1016/s0140-6736(03)14065-2.
    1. S. Hulley, D. Grady, T. Bush, et al., “Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women,” Journal of the American Medical Association 280, no. 7 (1998): 605–613, https://doi.org/10.1001/jama.280.7.605.
    1. D. Grady, D. Herrington, V. Bittner, et al., “Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow‐Up (HERS II),” Journal of the American Medical Association 288, no. 1 (2002): 49–57, https://doi.org/10.1001/jama.288.1.49.

LinkOut - more resources